Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent
Raju Subramanian(Gilead Sciences (United States)), Bill J. Smith(Gilead Sciences (United States)), Kelly Wang(Gilead Sciences (United States)), Tomáš Cihlář(Gilead Sciences (United States)), Scott A. Wolckenhauer(Gilead Sciences (United States)), Helen Yu(Hospital for Sick Children), M. Naveed Shaik(Pfizer (United States)), Anne Chester(Gilead Sciences (United States)), Jennifer Tang(Gilead Sciences (United States)), William Rowe(Gilead Sciences (United States)), Stephen R. Yant(Gilead Sciences (United States)), Winston C. Tse(Gilead Sciences (United States)), Andrew Mulato(Gilead Sciences (United States)), Bing Lu(Gilead Sciences (United States)), Martin S. Rhee(Gilead Sciences (United States)), Scott D. Schroeder(Gilead Sciences (United States)), Anna Chiu(Gilead Sciences (United States)), Jim Zheng(Gilead Sciences (United States)), Renu Singh, George Stepan(Gilead Sciences (United States))
Cited by 52
Related Papers
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
|Cell Reports|2020|541
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312